Multiple Sclerosis companies are Immune Response BioPharma, Clene Nanomedicine, Genzyme, ImStem Biotechnology, Rho, Inc., ...

Scientists have characterized the role of thousands of mutations in the BRCA2 cancer gene, findings that may help reassure ...

About Fexlamose Fexlamose is being developed as a chronic treatment for COPD and asthma in conjunction with standard therapies, to improve lung function, lessen symptoms and improve quality of life.

Cambridge Cognition Holdings plc (AIM: COG), the brain health software group, congratulates Bristol Myers Squibb, the global biopharmaceutical company, for its recent FDA approval of Cobenfy (KarXT™ ...

Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care ...

Licensing deals have risen in prominence in a restrained market environment. Is it desperation, or an important part of the ...

Truist raised the firm’s price target on Bristol Myers (BMY) to $65 from $62 and keeps a Buy rating on the shares as part of a broader research ...

By Sneha S K and Sriparna Roy (Reuters) -The U.S. Food and Drug Administration said on Friday that it has approved an ...

CytomX’s workforce cuts could leave the biotech with fewer than 75 employees as it focuses resources on its wholly owned ...

Cancer-focused CytomX Therapeutics Inc. will lay off 40% of its workforce — about 50 employees — to help extend its cash into ...

The firm is shifting its resources to fund and expand its Phase I clinical trial of givastomig in CLDN18.2-expressing advanced solid tumor patients.